HRAS and urinary bladder carcinoma: By using gene databases, pterostilbene was predicted to sensitize cisplatin-resistant bladder cancers with oncogenic HRAS. Among the bladder cancer cell lines stored in the PRISM database, the most effective cell line against pterostilbene is T24 (Figure 2C), a grade III human bladder cancer cell with mutant HRAS protein (G12V, ATCC).